IRIDEX (IRIX) Osake Kurssi

IRIDEX Corp is primarily active in the medical technology industry.

The main competitors of IRIDEX Corp in the market are Alcon Inc., Ellex Medical Lasers Ltd., and Lumenis Ltd.

IRIDEX Corp is a renowned medical technology company specializing in the development and commercialization of innovative laser systems for the treatment of various eye diseases. Founded in 1989, IRIDEX has since garnered a strong reputation for its cutting-edge products and advanced therapeutic solutions. The company boasts a rich history, marked by significant milestones and achievements in the field of ophthalmology. Guided by a commitment to revolutionize the way eye diseases are diagnosed and treated, IRIDEX remains at the forefront of the industry, continually striving to enhance patient outcomes through its state-of-the-art technologies.

IRIDEX Corp has achieved numerous significant milestones over the years. The company has successfully emerged as a leading provider of laser-based medical solutions, specializing in treating sight-threatening eye conditions. Notably, IRIDEX Corp introduced the innovative MicroPulse technology, which revolutionized the way retinal diseases are treated. Additionally, the company has expanded its product portfolio and global presence. IRIDEX Corp's dedication to technological advancements and commitment to enhancing patient outcomes have contributed to its position as a trusted name in ophthalmic healthcare.

IRIDEX Corp is primarily present in the United States.

IRIDEX Corp represents values of innovation, excellence, and patient-centricity. With a corporate philosophy centered around advancing patient care, IRIDEX Corp is committed to delivering cutting-edge medical solutions for eye diseases. The company strives to improve outcomes and enhance the quality of life for patients through the development and commercialization of minimally invasive laser-based medical devices. By combining state-of-the-art technology and a patient-first approach, IRIDEX Corp aims to revolutionize the treatment of retinal diseases and glaucoma. Through its commitment to innovation and dedication to improving patient outcomes, IRIDEX Corp has established itself as a leading player in the ophthalmic medical device industry.

Analyytikot asettavat tällä hetkellä IRIDEX-osakkeelle keskimääräisen tavoitehinnan 2,04 USD (mediaani: 2,04 USD), mikä merkitsee +226,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 6 analyytikkoarvioon.

IRIDEX Analyytikkojen kursstavoitteet 2026

7 analyytikkoa arvioi tällä hetkellä IRIDEX-osaketta: 6 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat IRIDEX-yhtiöltä 52,52 M USD liikevaihtoa ja −0,12 USD osakekohtaista tulosta.

IRIDEX Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla IRIDEX-osake noteerataan hintaan 0,55 EUR (0,63 USD).

IRIDEX-osake (IRIX) on listattuna 1 pörssissä, muun muassa: NASDAQ (IRIX).

IRIDEX Corporation is a leading company specializing in the development, manufacture, and sale of medical laser systems and accessories. The company offers a wide range of products and services targeting various customers including doctors, ophthalmologists, medical device providers, and surgical centers worldwide. The company specializes in two main divisions: ophthalmology and aesthetic dermatology. In the ophthalmology division, IRIDEX offers a variety of laser systems and system accessories focusing on the treatment of retinal diseases and glaucoma, as well as cosmetic and therapeutic procedures. The company is particularly known for its proven laser system, the "PASCAL Photocoagulator," which is considered one of the most advanced retinal laser therapy systems. IRIDEX's ophthalmology division also offers other innovative products such as the IRIS Medical SoftFit Gonioscope for glaucoma diagnosis. IRIDEX is also active in aesthetic dermatology, offering products for hair removal, wrinkle treatment, vascular treatment, and the treatment of common skin issues like acne. The flagship products in this area are the "GentleMAXPro" laser system and the multifunctional aesthetic system "Apogee+." The company generates revenue through the sale of devices and accessories, including consumables, as well as services such as training and support. IRIDEX sells its products in over 100 countries, targeting markets in Europe, North America, and Asia. It serves its customers directly through its subsidiaries or through distribution partners. The company's business model is based on a combination of research and development, marketing and sales, customer care, and efficiency assurance in production. IRIDEX engineers constantly work to improve the effectiveness and usability of their products, creating patient-oriented solutions based on scientifically proven results. IRIDEX has also entered into distribution agreements with global distributors to market and sell its products worldwide. IRIDEX aims to improve the standards and procedures of laser technology and continuously optimize patient care in the fields of ophthalmology and aesthetic dermatology. The company strives to build long-term relationships with clinicians and scientists to deliver advanced solutions in the medical device industry. In summary, IRIDEX is a company dedicated to advanced laser technology and accessories for ophthalmology and aesthetic dermatology. Through continuous innovation and collaborative partnerships, the company aims to support its customers with patient-oriented solutions. IRIDEX has already achieved significant milestones in its goal of establishing itself as the leading product line for global ophthalmology and aesthetic dermatology. IRIDEX Corporation is a leading company specialized in the development, manufacturing, and sale of medical laser systems and accessories. The company offers a wide range of products and services targeting various customers, including doctors, ophthalmologists, medical device providers, and surgical centers worldwide. The company is specialized in two main divisions: Ophthalmology and aesthetic dermatology. In the ophthalmology division, IRIDEX offers a variety of laser systems and system accessories focusing on the treatment of retinal diseases and glaucoma, as well as cosmetic and therapeutic procedures. The company is particularly known for its proven laser system, the "Pascal Photocoagulator," which is considered one of the most advanced retinal laser therapy systems. The IRIDEX ophthalmology division also offers other innovative products, such as the IRIS Medical SoftFit Gonioscope for glaucoma diagnosis. IRIDEX is also active in aesthetic dermatology, where it offers products for hair removal, wrinkle treatment, vascular treatment, and the treatment of common skin problems such as acne. The flagship products in this area are the "GentleMAXPro" laser system and the multifunctional aesthetic system "Apogee+." The company generates revenue through the sale of devices and accessory products, including consumables, and services such as training and support. IRIDEX sells its products in more than 100 countries, targeting markets in Europe, North America, and Asia. It serves its customers directly through its subsidiaries or through distribution partners. The company's business model is based on a combination of research and development, marketing and sales, customer support, and efficiency assurance in production. IRIDEX engineers constantly work to improve the effectiveness and usability of their products, creating patient-oriented solutions based on scientifically proven results. IRIDEX has also entered into distribution agreements with global distributors to market and sell its products worldwide. IRIDEX aims to improve the standards and procedures of laser technology and continuously optimize patient care in the fields of ophthalmology and aesthetic dermatology. The company strives to build long-term relationships with clinicians and scientists to deliver advanced solutions in the medical device industry. In summary, IRIDEX is a company dedicated to advanced laser technology and accessory products for ophthalmology and aesthetic dermatology. Through continuous innovation and collaborative partnerships, the company aims to support its customers with patient-oriented solutions. IRIDEX has already achieved significant milestones in its goal of establishing itself as a leading product line for global ophthalmology and aesthetic dermatology.

odotettu liikevaihto IRIDEX on 52,52 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto IRIDEX on −2,06 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

IRIDEX:n hinta-voitto-suhde (P/E) on tällä hetkellä −5,21. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan IRIDEX-osakkeen arvostusta.

IRIDEX:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,20. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii IRIDEX-osakkeen arvostuskennuslukuna.

IRIDEX:n Eulpool-laatuscore on 2/10.

IRIDEX:n ISIN on US4626841013. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

IRIDEX:n WKN on 912341. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

IRIDEX:n ticker on IRIX. Tämä pörssinoteeraus käytetään IRIDEX-osakkeiden kauppaan pörssissä.

IRIDEX maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

IRIDEX kuuluu sektoriin 'Terveydenhuolto'.

IRIDEX:n osingot jaetaan valuutassa USD.